A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

被引：0
|
作者：
de Motta, Laura Lores [1 ]
Van Asten, Freekje [1 ]
Muether, Philipp S. [2 ]
Smailhodzic, Dzenita [1 ]
Chen, John C. [3 ]
Koenekoop, Robert K. [3 ,4 ,5 ]
Fauser, Sascha [2 ]
Hoyng, Carel C. B. [1 ]
Den Hollander, Anneke I. [1 ,6 ]
de Jong, Eiko [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands
[2] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany
[3] McGill Univ, Dept Ophthalmol, Ctr Hlth, Montreal, PQ H3A 2T5, Canada
[4] McGill Univ, Dept Pediat Surg, Ctr Hlth, Montreal, PQ, Canada
[5] McGill Univ, Dept Human Genet, Ctr Hlth, Montreal, PQ, Canada
[6] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2015年 / 56卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3990
引用
收藏
页数：3
相关论文
共 50 条
  • [41] PROGNOSTIC FACTORS AND OUTCOME OF INTRAVITREAL RANIBIZUMAB TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Narayan, Daniel
    Meucke, James
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2012, 40 : 113 - 113
  • [42] COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Stepien, Kimberly E.
    Rosenfeld, Philip J.
    Puliafito, Carmen A.
    Feuer, William
    Shi, Wei
    Al-Attar, Luma
    Dubovy, Sander R.
    Murray, Timothy G.
    Davis, Janet L.
    Lee, Wen-Hsiang
    Schwartz, Stephen G.
    Smiddy, William E.
    Berrocal, Audina M.
    Flynn, Harry W., Jr.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (08): : 1067 - 1073
  • [43] Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration
    Heroman, J. Wesley
    Kaplan, Henry J.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 491 - 497
  • [44] Evaluation of Port Delivery System with ranibizumab for the treatment of neovascular age-related macular degeneration
    Patel, Annika J.
    Pieramici, Dante J.
    Bagheri, Nika
    THERAPEUTIC DELIVERY, 2021, 12 (03) : 191 - 200
  • [45] LONG-TERM EFFICACY OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Chang, Andrew A.
    Chew, Jamie
    Syed, Adil
    Joachim, Nichole
    Li, Haitao
    Broadhead, Geoffrey K.
    Zhu, Meidong
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 41 : 98 - 98
  • [46] Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision
    Sorensen, Torben Lykke
    Kemp, Henrik
    ACTA OPHTHALMOLOGICA, 2011, 89 (01) : E97 - E97
  • [47] Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme
    Wolf, A.
    Reznicek, L.
    Muhr, J.
    Ulbig, M.
    Kampik, A.
    Haritoglou, C.
    OPHTHALMOLOGE, 2013, 110 (08): : 740 - 745
  • [48] Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed
    Farah, Samer E.
    OPHTHALMIC SURGERY LASERS & IMAGING, 2008, 39 (04) : 294 - 298
  • [49] Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration
    Timothy Y. Y. Lai
    Wai-Man Chan
    David T. Liu
    Dennis S. Lam
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2007, 245 : 1877 - 1880
  • [50] Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
    Hurley S.F.
    Matthews J.P.
    Guymer R.H.
    Cost Effectiveness and Resource Allocation, 6 (1)
12345